Oral Antiplatelet Treatment in STEMI: Current Practice and Future Considerations
Related Experiment Video
Updated: Mar 20, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Ioanna Xanthopoulou, Dimitrios Alexopoulos1
1Attikon University Hospital, Cardiology Department, Athens, Greece.
Insights
For ST-elevation myocardial infarction patients, prasugrel and ticagrelor are preferred P2Y12 inhibitors over clopidogrel when used with aspirin. Optimal timing and duration of oral antiplatelet therapy require further investigation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- ST-segment elevation myocardial infarction (STEMI) patients are high-risk.
- Effective antiplatelet therapy is crucial alongside primary percutaneous coronary intervention.
Purpose of the Study:
- Review current evidence on oral antiplatelet therapy in STEMI.
- Discuss clinical efficacy, safety, and future perspectives.
Main Methods:
- Literature review of clinical trials and pharmacodynamic/pharmacokinetic data.
- Analysis of oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in STEMI patients.
Main Results:
- Prasugrel and ticagrelor are preferred P2Y12 inhibitors over clopidogrel when added to aspirin.
- Concerns exist regarding delayed onset of action and morphine's impact on efficacy.
- Prolonged antiplatelet therapy beyond one year may offer clinical benefits.
Conclusions:
- Oral P2Y12 inhibitors are viable options for STEMI patients.
- Further research is needed to optimize their use regarding agent selection, timing, and duration.
Background:
Patients with ST-segment elevation myocardial infarction represent a high-risk population and an effective antiplatelet treatment adjunctive to primary percutaneous coronary intervention is of paramount importance.
Methods:
This topic will review the current evidence on clinical efficacy and safety of oral antiplatelet therapy in patients with an acute ST-segment elevation myocardial infarction. Unsettled issues and future perspectives for their use in these patients are also discussed.
Results:
Added to aspirin, clopidogrel, prasugrel and ticagrelor represent viable options regarding oral P2Y12 inhibition, with prasugrel and ticagrelor being preferred over clopidogrel, according to results of large randomized clinical trials. Early clinical efficacy of oral antiplatelet agents in STEMI patients has been questioned, mainly because of their delayed onset of action in the clinical setting of ST-segment elevation myocardial infarction and the recently described adverse effect of morphine on their pharmacodynamic/pharmacokinetic profile. Whether these agents should be administered beyond 1 year after the index event is also under discussion, as there is clinical evidence that prolonged administration may be associated with clinical benefit.
Conclusion:
Use of oral P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction still faces questions and future research is needed to establish which, when and how should be administered in this clinical setting.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Angina IV: Management